• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Moderna Set to Join S&P 500

    7/15/21 7:01:00 PM ET
    $SPGI
    $ALXN
    $AZN
    $MRNA
    Finance: Consumer Services
    Finance
    Major Pharmaceuticals
    Health Care
    Get the next $SPGI alert in real time by email

    NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    July 21, 2021

    S&P 500

    Addition

    Moderna

    MRNA

    Health Care



    S&P 500

    Deletion

    Alexion Pharmaceuticals

    ALXN

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/moderna-set-to-join-sp-500-301335329.html

    SOURCE S&P Dow Jones Indices

    Get the next $SPGI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPGI
    $ALXN
    $AZN
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    Moderna Inc.
    $MRNA
    1/29/2025$99.00 → $51.00Buy → Neutral
    Goldman
    More analyst ratings

    $SPGI
    $ALXN
    $AZN
    $MRNA
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/9/25 11:23:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/7/25 9:53:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/6/25 9:15:27 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      6/17/24 4:04:40 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Client Officer Moore Sally sold $255,148 worth of shares (500 units at $510.43), decreasing direct ownership by 9% to 5,131 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      5/7/25 5:33:08 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • EVP, Chief Legal Officer Kemps Steven J sold $1,017,640 worth of shares (2,000 units at $508.82), decreasing direct ownership by 22% to 7,249 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      5/7/25 5:32:23 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • Director Peterson Douglas L. sold $9,631,629 worth of shares (19,173 units at $502.35), decreasing direct ownership by 28% to 48,842 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      5/2/25 4:03:26 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Financials

    Live finance-specific insights

    See more
    • S&P Global Declares Second Quarter Dividend

      NEW YORK, May 6, 2025 /PRNewswire/ -- The Board of Directors of S&P Global (NYSE:SPGI) has approved a cash dividend on the Corporation's common stock for the second quarter of 2025. The dividend of $0.96 is payable on June 11, 2025, to shareholders of record on May 28, 2025. The annualized dividend rate is $3.84 per share. The Company has paid a dividend each year since 1937 and is one of fewer than 30 companies in the S&P 500® that has increased its dividend annually for more than 50 years. About S&P Global: S&P Global (NYSE:SPGI) provides essential intelligence. We enable governments, businesses and individuals with the right data, expertise and connected technology so that they can make

      5/6/25 4:39:00 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • S&P Global Announces Intent to Separate Mobility Segment into Standalone Public Company

      S&P Global Strongly Positioned to Drive Continued Profitable Growth and Value Creation Across Four Core BusinessesS&P Global Mobility to Be an Automotive Data and Technology Leader with Flexibility to Pursue Near- and Long-Term Growth OpportunitiesCompany Separately Reports First Quarter 2025 Results; Conference Call Today at 8:30 a.m. ETNEW YORK, April 29, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced its intent to separate S&P Global Mobility ("Mobility") from S&P Global to drive long-term value creation. The planned separation is expected to result in Mobility becoming a standalone public company.

      4/29/25 7:22:00 AM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • S&P Global Reports First Quarter Results, Announces Intended Separation of Mobility Division

      NEW YORK, April 29, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today reported first quarter results. The Company's earnings release and supplemental materials are available at http://investor.spglobal.com/Quarterly-Earnings. Supplemental Information/Conference Call/Webcast Details: The Company's senior management will review the first quarter 2025 earnings results on a conference call scheduled for today, April 29, at 8:30 a.m. EDT. Additional information presented on the conference call, as well as the Company's Supplemental slide content may be found on the Company's Invest

      4/29/25 7:20:00 AM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      4/10/24 2:03:52 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by S&P Global Inc. (Amendment)

      SC 13G/A - S&P Global Inc. (0000064040) (Subject)

      2/13/24 5:13:53 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      2/7/24 8:42:56 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

      Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs. BCG alone Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.​ The trial was not statistically powered to formally test ov

      5/9/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Changing Restrictions on Russian Gas to Europe Would Disproportionately Impact US LNG Exports, New S&P Global Commodity Insights Study Finds

      Future course of sanctions and flow of Russian gas to Europe could impact up to $120 billion of investment and 29 MMtpa for future U.S. LNG projects WASHINGTON, May 8, 2025 /PRNewswire/ -- The United States, which currently supplies half of Europe's liquefied natural gas (LNG) imports and roughly 15% of the continent's total gas supply, would be disproportionately impacted if current restrictions on Russian gas and LNG were to change, a new S&P Global Commodity Insights study finds. The report, U.S. LNG Exports at Risk: Potential Unwinding of Sanctions on Russian Natural Gas found that, under an "Opening the Taps" scenario where U.S. sanctions on Russian natural gas pipeline and LNG exports

      5/8/25 11:41:00 AM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

      AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positi

      5/7/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on S&P Global with a new price target

      BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $600.00

      4/10/25 8:19:38 AM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • Citigroup initiated coverage on Moderna with a new price target

      Citigroup initiated coverage of Moderna with a rating of Neutral and set a new price target of $40.00

      3/13/25 8:15:14 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Okta Set to Join S&P MidCap 400

      NEW YORK, April 28, 2025 /PRNewswire/ -- Okta Inc. (NASD: OKTA) will replace Berry Global Group Inc. (NYSE:BERY) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, May 1. S&P 500 constituent Amcor plc (NYSE:AMCR) is acquiring Berry Global Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 1, 2025 S&P MidCap 400 Addition Okta OKTA Information Technology May 1, 2025 S&P MidCap 400 Deletion Berry Global Group BERY Materials For more information about S&P Dow Jon

      4/28/25 6:07:00 PM ET
      $AMCR
      $BERY
      $OKTA
      $SPGI
      Miscellaneous manufacturing industries
      Consumer Discretionary
      Plastic Products
      Industrials
    • S&P Global agrees to acquire ORBCOMM's Automatic Identification System business, strengthening its supply chain and maritime offerings

      NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- S&P Global (NYSE:SPGI) today announced an agreement to acquire the Automatic Identification System (AIS) data services business of ORBCOMM Inc. The AIS business is a leading provider of satellite data services used to track and monitor vessels, enhancing maritime visibility and delivering critical insights that support business intelligence and decision-making for government and commercial clients worldwide. Since 2004, ORBCOMM's AIS vessel tracking technology has incorporated high-quality, proprietary data with satellite and terrestrial based coverage. Its AIS solutions are utilized for diverse applications such as supply chain visibility, mar

      4/24/25 8:05:47 AM ET
      $SPGI
      Finance: Consumer Services
      Finance